ראש המרכז האמריקני לבקרה ומניעת מחלות (CDC) אישרה מתן חיסוני בוסטר גם למי שלא סובל ממחלות רקע  

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in:

individuals 65 years of age and older;
individuals 18 through 64 years of age at high risk of severe COVID-19; and
individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.

The CDC's Advisory Committee on Immunization Practices unanimously voted 15-0 to recommend booster shots for adults 65 and up. ACIP also voted 13-2 that individuals ages 50-64 with underlying health conditions should have access to the vaccine booster shot.